What Does Billionaire Nelson Peltz Think Of Legg Mason?

TRIAN PARTNERSAccording to a filing with the SEC, billionaire Nelson Peltz’s Trian Partners is down to 12.9 million shares of Legg Mason, Inc. (NYSE:LM). The fund still owns 9.5% of the shares outstanding, and according to a statement issued by Trian it did not technically sell shares but transferred ownership to an investor. At the end of June Trian had reported a position of 14.7 million shares on the fund’s 13F filing (find more stocks owned by Trian Partners), making it one of the fund’s top ten holdings at that time. However, the timing of this new filing is interesting as in mid-September Legg Mason had announced that its CEO would be leaving the asset manager and investment advisor effective October 1st. We have to wonder if there is a connection between Trian’s transaction- even if it was not driven by Peltz- and the management shakeup.

Trian has stated that it continues to consider Legg Mason, Inc. a good investment, even as the stock has only risen 1% this year while the S&P 500’s gain has approached 15%. In the first quarter of the company’s fiscal year, which ended in June, Legg Mason reported that revenue had fallen 12% from the same period a year ago. Investment advisory fees and distribution fees, the two primary sources of business, were both down. The company was able to cut costs- in particular, compensation and benefits were down 10%- but the existence of some fixed costs brought operating income down 24%. Earnings were negative, but this was entirely due to a loss on debt extinguishment; still, we would say that the company is struggling after growing its earnings at only a 4% annualized rate between its fiscal year ending in March 2010 and its fiscal year ending in March 2012.

Legg Mason, Inc. trades at 11 times forward earnings estimates, but this depends on the company achieving earnings growth this year over last year and then delivering a 55% increase in earnings per share next year. Even with the loss on debt extinguishment being non-recurring, the recent history of revenue and operating income do not look encouraging to us.

Our database of 13F filings shows other interest in Legg Mason at the end of the second quarter of the year. Billionaire David Einhorn’s Greenlight Capital owned 3.4 million shares, a very small decrease from what the fund had owned at the beginning of April, while Israel Englander’s Millennium Management raised its stake by 69% to a total of 1.1  million shares. See more stock picks from Greenlight Capital and Millennium Management.

Legg Mason can be compared to BlackRock, Inc. (NYSE:BLK), Charles Schwab Corp (NYSE:SCHW), Franklin Resources, Inc. (NYSE:BEN), and T. Rowe Price Group, Inc. (NASDAQ:TROW) to see if any of these peers offer a better value. For the most part, these companies are seeing the same poor industry dynamics as Legg Mason: BlackRock and Franklin Resources both saw their revenue and earnings fall in their most recent quarter compared to the same period a year ago. However, they do not seem to have been as hard hit as their revenue declines were smaller and their earnings declines were smaller than Legg Mason’s fall in operating income. At forward P/Es of 12 to 13, they are priced at about the same level and we think they could be safer investments. Charles Schwab and T. Rowe Price are considerably more expensive than these three companies, as both of these pairs trade at 17 times analyst earnings expectations for next year. While both of these companies grew their revenue and earnings last quarter versus a year earlier, that degree of a price premium over Legg Mason might be too high and their dividend yields are only a hair higher.

Trian says it’s not really selling out of Legg Mason, but we think it could be a smart idea to do so. Even if Wall Street analysts are right about its prospects- 55% EPS growth next fiscal year over this one- it doesn’t trade much cheaper than the more stable (and larger) BlackRock and Franklin Resources.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!